Cologne drug industry letter in violation of the claim or the next "Foshan lighting"

Recently, the Cologne pharmaceutical industry (market, interrogation) received the SFC's administrative ticket. The punishment book shows that the Cologne pharmaceutical industry to conceal the relationship between the transaction amount of up to 650 million yuan, than last year caused a stir in the securities of Foshan Lighting (market, interrogation) letter to cover the illegal money involved in the amount of about 260 million yuan plot more serious. In this regard, activist lawyers believe that, according to the share price decline, the number of shareholders at that time, it is expected that the branch-LUN pharmaceutical industry will also face tens of millions of shareholders claim. Two big letter of the issue was punished June 4, 2014 night, Sichuan Cologne Pharmaceutical Co., Ltd. announced the receipt of the SFC "Administrative penalty decision" ([2014]49 number). The SFC found that the illegal facts of the drug industry in Cologne include two points. First, the company's relevant temporary information disclosure is untrue. March 15, 2011, Cologne released the "on the use of super raise funds for the acquisition of June Jian Plastic Co., Ltd." Notice of the disclosure of the Cologne Pharmaceutical and Congzhou Plastic Limited Liability company (hereinafter referred to as "June Jian Plastic") The original shareholder of Sichuan Huifeng Investment Development Co., Ltd. (hereinafter referred to as "Huifeng investment") has no related transactions. After investigation, the Cologne pharmaceutical industry and Huifeng investment constitute a relationship, therefore, the Cologne pharmaceutical industry disclosed its original shareholder Huifeng investment with Gunjian plastic is not related to the transaction of information is untrue, the Cologne pharmaceutical industry in violation of the Securities Act 67th of the provisions. Secondly, there are major omissions in the 2010 Annual report of the Cologne pharmaceutical industry and the annual Report 2011. The 2010 Annual report of the Cologne pharmaceutical industry and the annual Report 2011 did not disclose the relationship and associated transactions with Gunjian plastics. After investigation, the Cologne pharmaceutical industry and Gunjian plastic composition, 2010 and 2011, the Cologne pharmaceutical industry at fair prices to Gunjian plastic plastic portfolio cover 238,855,028 54 Yuan and 414,129,974 02 yuan. The above-mentioned acts of the Cologne pharmaceutical industry are a major omission and violate the provisions of article 63rd of the Securities Act. Based on the above facts, the SFC decided to give a warning to the Cologne pharmaceutical industry, and a fine of 300,000 yuan, responsible for the executive also received warnings, fines and other penalties. A huge loss of stock prices May 4, 2013, the Cologne pharmaceutical companies received regulatory decisions. May 21, 2013, the Cologne pharmaceutical company received the SFC investigation notice. On the night of June 4, 2014, the company received a penalty decision from the SFC. As the dust settles for these administrative measures, the company's share price has also begun to sit on the roller coaster. Historical transactions show that March 15, 2011, the Cologne drug Karma received 148.48 yuan/unit, the share price fell all the way, although April 29, 2011 10 shares to increase 10 shares, but the closing price of May 3, 2013 only 63.4 yuan/unit, June 4, 2014 reported 37.69 yuan/shares, investors lost heavy. Shanghai New Hope Shanda law firm Song Yixin lawyer pointed out that, according to the Securities Law and the Supreme Court of Justice interpretation of false statements, the Cologne pharmaceutical industry letter to cover illegal acts constituteSecurities misrepresentation, investors who are injured in the interest can sue the Ke LUN pharmaceutical claim for losses (including investment balance, commission, interest and stamp loss). Song Yixin said that, according to judicial interpretation, in the period from March 15, 2011 to May 4, 2013 to buy the shares of the Cologne, and after May 5, 2013 sold or continued to hold, and the loss of investors can sue the claim, the jurisdiction of the Court is Chengdu. Irregularities and the height of Foshan lighting similar in addition, Zhejiang Yufeng law firm Kingjian Lawyer pointed out that the Cologne pharmaceutical industry and Foshan lighting letter is similar to the illegal plot. Among them, Foshan lighting letter covering the illegal amount of money involved about 260 million yuan, the current encounter more than 1300 shareholders to sue for 180 million yuan, the Cologne pharmaceutical industry to conceal the relationship between the transaction amount of up to 650 million yuan, more serious violations than Foshan lighting, according to the share price decline, the number of shareholders, It is expected that the branch LUN pharmaceutical industry will also face tens of millions of shareholders claim. Li said that at present, there are a number of shareholders to inquire about claims, loss amount of tens of thousands of yuan, the bill and other claims materials are being prepared, by mail, in which, Hangzhou shareholders, Ms. Han loss of up to 360,000 yuan, she in the period from March 15, 2011 to May 4, 2013 to buy and sell the Coulomb pharmaceutical stocks The maximum transaction price of $149.45/unit, according to the judicial interpretation, the lawyer initially estimated that she can claim the amount of 360,000 yuan. Li also said that Cologne pharmaceutical industry is the current year after the Purple Medicine (market, inquiry), the second only face the stock of the medical shareholders claim, there are currently dozens of shareholders to the Changchun Institute of Medicine to sue the purple Xin pharmaceutical industry, this fully shows that shareholders in accordance with the awareness of legal rights are constantly awakening. What fees does the shareholder claim? "Investment Express" reporter reminded the vast number of shareholders, the proposed prosecution of the investors should provide a copy of the identity card, Shenzhen stock Exchange shareholder card copy, stamped Securities company Sales Department Seal of the Stock Exchange Statement original (from the first buy "cologne" printing to the present), contact phone and address zip code. Free Audit, the lawyer will be in line with the terms of the claim, decided to entrust the action of investors, further provide relevant litigation documents. Li told reporters that in such cases, the cost of litigation for shareholders is mainly in the prosecution of the court charges, according to the State Council "litigation fee payment Method" stipulates that the costs of litigation generally in the amount of 2% of the claim, such as the claim of 20,000 yuan, the advance of the litigation fee of 300 yuan, the claim of 100,000 yuan, the cost of The litigation fee is ultimately borne by the losing party. So far, the majority of such cases have been borne by the defendant company. "With regard to legal fees, in fact, investors do not have too much concern, commissioned professional lawyers acting in such cases, usually using the risk agent, that is, lawyers do not charge fees in advance, only in case of winning, shareholders receive reparations, and then agreed to the two sides of the appropriate proportion of payment of legal fees (including travel expenses). "said the lawyer.